➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Dow
Merck
Medtronic
Johnson and Johnson

Last Updated: August 1, 2021

DrugPatentWatch Database Preview

SARAFEM Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

When do Sarafem patents expire, and what generic alternatives are available?

Sarafem is a drug marketed by Eli Lilly And Co and Apil and is included in two NDAs.

The generic ingredient in SARAFEM is fluoxetine hydrochloride. There are twenty-seven drug master file entries for this compound. Sixty-one suppliers are listed for this compound. Additional details are available on the fluoxetine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Sarafem

A generic version of SARAFEM was approved as fluoxetine hydrochloride by APNAR PHARMA LP on August 2nd, 2001.

  Try it Free

Drug patent expirations by year for SARAFEM
Drug Prices for SARAFEM

See drug prices for SARAFEM

Drug Sales Revenue Trends for SARAFEM

See drug sales revenues for SARAFEM

Recent Clinical Trials for SARAFEM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Torrent Pharmaceuticals LimitedPhase 1
University of PennsylvaniaPhase 4
National Institute of Mental Health (NIMH)Phase 4

See all SARAFEM clinical trials

Pharmacology for SARAFEM
Paragraph IV (Patent) Challenges for SARAFEM
Tradename Dosage Ingredient NDA Submissiondate
SARAFEM CAPSULE;ORAL fluoxetine hydrochloride 018936
PROZAC CAPSULE;ORAL fluoxetine hydrochloride 018936

US Patents and Regulatory Information for SARAFEM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly And Co SARAFEM fluoxetine hydrochloride CAPSULE;ORAL 018936-007 Jul 6, 2000 DISCN Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Apil SARAFEM fluoxetine hydrochloride TABLET;ORAL 021860-002 May 19, 2006 DISCN Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Eli Lilly And Co SARAFEM fluoxetine hydrochloride CAPSULE;ORAL 018936-008 Jul 6, 2000 DISCN Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Apil SARAFEM fluoxetine hydrochloride TABLET;ORAL 021860-001 May 19, 2006 DISCN Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for SARAFEM

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eli Lilly And Co SARAFEM fluoxetine hydrochloride CAPSULE;ORAL 018936-008 Jul 6, 2000 ⤷  Try it Free ⤷  Try it Free
Eli Lilly And Co SARAFEM fluoxetine hydrochloride CAPSULE;ORAL 018936-007 Jul 6, 2000 ⤷  Try it Free ⤷  Try it Free
Eli Lilly And Co SARAFEM fluoxetine hydrochloride CAPSULE;ORAL 018936-007 Jul 6, 2000 ⤷  Try it Free ⤷  Try it Free
Eli Lilly And Co SARAFEM fluoxetine hydrochloride CAPSULE;ORAL 018936-008 Jul 6, 2000 ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Dow
Merck
Medtronic
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.